- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04102254
Thalamic Stimulation for Epilepsy Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this research is to examine the physiologic underpinnings of deep brain stimulation of the anterior nucleus of the thalamus (ANT), a method reducing seizures in adults diagnosed with medically refractory epilepsy. In this study, the investigator aims to perform cortical stereo electroencephalogram (sEEG) recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity. Together, this knowledge will advance ANT DBS therapy by providing a physiologic basis for patient selection for ANT DBS, while identifying brain signals and stimulation patterns that can be used to develop novel methods for ANT DBS.
Approximately 3 million people in the United States experience epilepsy. Despite medical therapy, up to 30% of these patients continue to experience recurrent seizures. In this medically refractory population, tissue resection or ablation offer a high likelihood of seizure freedom, if a single epileptogenic focus can be precisely identified. For patients who are not candidates for resection or ablation, or those who continue to have seizures after these treatments, neuromodulation represents an alternative therapeutic option. One such therapy, deep brain stimulation (DBS) has been approved for around 5 years in Europe and was recently approved in the United States as a treatment for medically refractory epilepsy.
A number of potential DBS targets are being investigated, particularly, the ANT, which consists of the anteroventral, anterodorsal, and anteromedial nuclei. The ANT was recognized as a potential target because of its central connectivity to cortical regions where seizures often originate. Several pilot studies and recent trials have demonstrated 5-year efficacy and safety outcomes for ANT DBS. In a large randomized controlled study of ANT stimulation with long-term follow-up, there was a 56% median seizure reduction at the 2 year, and a 69% median and seizure reduction at the 5 year, in patients with drug-resistant focal epilepsy. This study also suggested that patients with temporal lobe epilepsy achieved greater benefit than those with extra-temporal or multifocal seizures. Since these pivotal trials, DBS of the ANT has emerged as a promising therapy for focal drug resistant epilepsy, however, its basic mechanism of action is unclear. One study which examined cortical local field potentials recordings during high-frequency ANT stimulation (130 Hz), has suggested that epileptic network desynchronization is a potential mechanism of DBS of the ANT.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Health System
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ANT recording and stimulation
Up to 15 adult patients who present to Duke Neurosurgery for routine seizure location using sEEG will be asked to enroll in this pilot study of ANT recording and stimulation.
Once enrolled in the trial, subjects will have additional placement of two thalamic electrodes during the course of standard sEEG placement surgery.
Patients routinely remain hospitalized for 7-14 days after sEEG placement, during which time their seizure medications are tapered.
Continuous neural recordings are made through the sEEG electrodes for the purposes of seizure localization during the entire time the depth electrodes are in place.
Up to three times daily, standard intermittent high-frequency stimulation [130 Hertz (Hz), 90-millisecond pulse width, and 2 milliamps (mA) intensity] will be performed with a 60-seconds on and a 300-seconds off cycle following surgery up to the entire length of sEEG monitoring.
|
In this study, the investigator aims to perform sEEG recordings during simultaneous ANT recording and stimulation to better understand the following: 1) how the ANT is involved in various seizure types; 2) which cortical regions are modulated by established ANT stimulation patterns; and 3) how novel ANT stimulation patterns modify epileptogenic cortical activity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent changes from baseline in power (dB)
Time Frame: Measurements will be made 7-14 days following surgery for sEEG placement
|
Differences of greater than 25% in magnitude in percent mean change in power between primary regions of interest will be reported.
A maximum of 20 comparisons will be made.
|
Measurements will be made 7-14 days following surgery for sEEG placement
|
|
Percent changes from baseline in rates of interictal spikes
Time Frame: Measurements will be made 7-14 days following surgery for sEEG placement
|
Differences of greater than 25% in magnitude in percent mean change in rates of interictal spikes between primary regions of interest will be reported.
A maximum of 20 comparisons will be made.
|
Measurements will be made 7-14 days following surgery for sEEG placement
|
|
Percent changes from baseline in rates of high frequency oscillations
Time Frame: Measurements will be made 7-14 days following surgery for sEEG placement
|
Differences of greater than 25% in magnitude in percent mean change in rates of high frequency oscillations between primary regions of interest will be reported.
A maximum of 20 comparisons will be made.
|
Measurements will be made 7-14 days following surgery for sEEG placement
|
|
Percent changes in connectivity density
Time Frame: Measurements will be made 7-14 days following surgery for sEEG placement
|
Changes of greater than 25% in magnitude in connectivity density on versus off stimulation in primary regions of interest will be reported.
A maximum of 20 comparisons will be made.
|
Measurements will be made 7-14 days following surgery for sEEG placement
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Derek Southwell, M.D., Ph.D., Duke Health
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00103374
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustNot yet recruitingEpilepsy Intractable | Epilepsy in Children
-
University Hospital, LilleCompletedFocal Epilepsy | Epilepsy IntractableFrance
-
Massachusetts General HospitalBoston University; National Institute of Neurological Disorders and Stroke...CompletedEpilepsy | Epilepsy; Seizure | Rolandic Epilepsy | Rolandic Epilepsy, Benign | Centrotemporal Epilepsy | Centrotemporal; EEG Spikes, Epilepsy of ChildhoodUnited States
Clinical Trials on ANT recording and stimulation
-
Prof. Dr. Volker Arnd CoenenUniversity of FreiburgRecruiting
-
Coherence Neuro Australia Pty LimitedRoyal Melbourne Hospital, AustraliaRecruitingA First-in-Human Study of the CIPHER System During Brain Surgery for Newly Diagnosed Glioma (CIPHER)Glioma | Tumor | Brain | ElectrocorticographyAustralia
-
Stanford UniversityNational Institute of Mental Health (NIMH)CompletedPTSD | Fear | Panic DisorderUnited States
-
Women and Infants Hospital of Rhode IslandRecruitingMaternal Behavior | Language Development | Feeding; Difficult, Newborn | Mother-Infant Interaction | Language DelayUnited States
-
Istituto Nazionale Assicurazione contro gli Infortuni...RecruitingUpper Limb AmputeesItaly
-
AllerganCompletedHyperhidrosisUnited States
-
Anterios Inc.Completed
-
Anterios Inc.Completed
-
Swiss Federal Institute of TechnologyUniversity of Zurich; cereneo center for Neurology and RehabilitationRecruitingParkinson Disease | Gait Disorders, NeurologicSwitzerland
-
University Hospital, CaenRecruitingPremature Birth | Neurodevelopmental DisordersFrance